Safety and Cost Analysis of Immunoglobulin Cessation Trials in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Individuals with CIDP should be counselled about the natural history of the disease and future scheduled, targeted cessation trials. A dedicated clinical infrastructure is vital to safely perform cessation trials.
Authors
- George Ransley
- Michael Peter Lunn (ORCID: https://orcid.org/0000-0003-3174-6027)
- Shiwen Koay (ORCID: https://orcid.org/0000-0002-0860-9211)
- Yi‐Chun Chen (ORCID: https://orcid.org/0000-0001-5192-6821)
- Laura Compton
- Aisling Carr
Institutions
- National Hospital for Neurology and Neurosurgery (GB)
- University College London (GB)
Publication Details
- Journal
- Journal of the Peripheral Nervous System
- Published
- 2025-02-18
- DOI
- https://doi.org/10.1111/jns.70007
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute for Health and Care Research
- University College London
- University College London Hospitals NHS Foundation Trust
- UCLH Biomedical Research Centre